Breaking News Instant updates and real-time market news.

AMGN

Amgen

$176.09

-0.74 (-0.42%)

13:40
06/16/19
06/16
13:40
06/16/19
13:40

Amgen announces BLINCYTO five-year overall survival data

Amgen announced the five-year overall survival analysis from the single-arm, Phase 2 BLAST study that evaluated BLINCYTO in patients with minimal residual disease-positive acute lymphoblastic leukemia. The study found that with a median follow-up of 59.8 months, the median OS for BLINCYTO-treated patients was 36.5 months. More than half of patients who achieved a complete MRD response following the first cycle of BLINCYTO treatment were alive at five years. These results from the largest prospective trial ever conducted in MRD-positive ALL were presented during an oral presentation at the 24th Annual Congress of the European Hematology Association in Amsterdam. The Phase 2 open-label BLAST study enrolled 116 patients with MRD-positive Philadelphia chromosome-negative B-cell precursor ALL in first or subsequent complete hematologic remission after at least three intensive chemotherapy blocks of treatment. Of the 116 enrolled patients, OS was evaluated for 110 patients with less than five percent leukemic blasts, including 74 patients who received hematopoietic stem cell transplantation in continuous complete remission after BLINCYTO treatment. Results presented at EHA showed that in 84 patients who achieved a complete MRD response, median OS was not reached compared to 14.4 months for those who had measurable MRD. Among patients with MRD in first complete remission, median OS was not reached for those who achieved a complete MRD response versus 10.6 months for those who did not achieve complete MRD response. Safety results among MRD-positive patients were consistent with the known safety profile of BLINCYTO.

  • 16

    Sep

AMGN Amgen
$176.09

-0.74 (-0.42%)

06/04/19
RHCO
06/04/19
NO CHANGE
Target $120
RHCO
Buy
Mirati Therapeutics price target raised to $120 from $85 at SunTrust
SunTrust analyst Peter Lawson raised his price target on Mirati Therapeutics (MRTX) to $120 and kept his Buy rating following yesterday's "encouraging" ASCO presentation by Amgen (AMGN) regarding its KRAS G12C inhibitor AMG 510. The analyst notes that the side effect profile and response to the treatment's lowest dose in AMG 510 are positive for Mirati's MRTX849, raising his probability Adjusted Peak Sales for the latter to $1.65B from $1.33B with probability of success little changed at 52%.
06/05/19
LEHM
06/05/19
NO CHANGE
Target $123
LEHM
Overweight
Mirati Therapeutics price target raised to $123 from $85 at Barclays
Barclays analyst Gena Wang raised her price target for Mirati Therapeutics (MRTX) to $123 from $85 saying Amgen's (AMGN) AMG510 data support KRAS G12C as a validated target, and the "impressive" data provide proof of concept for potentially single agent activity in non-small cell lung cancer. The analyst continues to believe that Mirati's MRTX849 could have a more favorable profile based on the preclinical results, including "longer half-life and good tissue penetration." She reiterates an Overweight rating on Mirati Therapeutics.
06/05/19
HCWC
06/05/19
NO CHANGE
Target $117
HCWC
Buy
Mirati Therapeutics price target raised to $117 from $84 at H.C. Wainwright
H.C. Wainwright analyst Edward White raised his price target for Mirati Therapeutics (MRTX) to $117 from $84 saying the positive data for Amgen's (AMGN) AMG 510 bode well for Mirati's MRTX849. The analyst believes the AMG 510 data "somewhat derisks" the development of MRTX849/ He raised his estimate for probability of success for MRTX849 to 20% from 10% and keeps a Buy rating on Mirati Therapeutics.
06/07/19
GUGG
06/07/19
DOWNGRADE
GUGG
Neutral
Guggenheim downgrades Mirati to Neutral following near-tripling of stock
As previously reported, Guggenheim analyst Michael Schmidt downgraded Mirati Therapeutics (MRTX) to Neutral from Buy, noting that the shares have nearly tripled since data were presented at the European Society for Medical Oncology, or ESMO, meeting in October. While Schmidt said Amgen's (AMGN) KRAS inhibitor Phase I data presented at the American Society of Clinical Oncology meeting validates MRTX849's potential mechanism of action, he sees a "lot of upside" priced in at the current valuation despite the remaining development risks. He also believes investor expectations have significantly increased ahead of Mirati's own Phase I data presentation in the second half of the year.

TODAY'S FREE FLY STORIES

RBNC

Reliant Bancorp

$22.46

-0.16 (-0.71%)

06:56
08/23/19
08/23
06:56
08/23/19
06:56
Initiation
Reliant Bancorp initiated  »

Reliant Bancorp initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

CLH

Clean Harbors

$75.14

-0.25 (-0.33%)

06:53
08/23/19
08/23
06:53
08/23/19
06:53
Initiation
Clean Harbors initiated  »

Clean Harbors resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROST

Ross Stores

$107.31

1.63 (1.54%)

06:53
08/23/19
08/23
06:53
08/23/19
06:53
Recommendations
Ross Stores analyst commentary  »

Ross Stores price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEB

Hemispherx

$1.89

-0.02 (-1.05%)

06:52
08/23/19
08/23
06:52
08/23/19
06:52
Hot Stocks
Hemispherx changes name to AIM ImmunoTech, effective September 3 »

Hemispherx Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BKE

The Buckle

$18.61

0.695 (3.88%)

06:50
08/23/19
08/23
06:50
08/23/19
06:50
Earnings
The Buckle reports Q2 EPS 34c, consensus 30c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

GPS

Gap

$17.75

0.79 (4.66%)

06:50
08/23/19
08/23
06:50
08/23/19
06:50
Recommendations
Gap analyst commentary  »

Gap price target lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

LNDC

Landec

$10.99

-0.07 (-0.63%)

06:50
08/23/19
08/23
06:50
08/23/19
06:50
Initiation
Landec initiated  »

Landec initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TELL

Tellurian

$9.19

0.9 (10.86%)

06:49
08/23/19
08/23
06:49
08/23/19
06:49
Downgrade
Tellurian rating change  »

Tellurian downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$203.43

-0.41 (-0.20%)

, ALXN

Alexion

$123.51

8.64 (7.52%)

06:48
08/23/19
08/23
06:48
08/23/19
06:48
Recommendations
Amgen, Alexion analyst commentary  »

Amgen deal for Alexion…

AMGN

Amgen

$203.43

-0.41 (-0.20%)

ALXN

Alexion

$123.51

8.64 (7.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 16

    Sep

  • 19

    Sep

  • 02

    Oct

  • 19

    Oct

FL

Foot Locker

$42.00

2.24 (5.63%)

06:47
08/23/19
08/23
06:47
08/23/19
06:47
Earnings
Foot Locker reports Q2 EPS ex-items 66c, consensus 67c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 19

    Sep

  • 25

    Sep

VWAGY

Volkswagen

$0.00

(0.00%)

06:47
08/23/19
08/23
06:47
08/23/19
06:47
Periodicals
Volkswagen looks for investment in China auto suppliers, Bloomberg says »

Volkswagen is considering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$18.91

-0.04 (-0.21%)

06:46
08/23/19
08/23
06:46
08/23/19
06:46
Recommendations
HP Inc. analyst commentary  »

HP Inc. price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

VMW

VMware

$148.15

0.11 (0.07%)

, PVTL

Pivotal Software

$13.69

0.01 (0.07%)

06:45
08/23/19
08/23
06:45
08/23/19
06:45
Recommendations
VMware, Pivotal Software, Carbon Black analyst commentary  »

VMware price target…

VMW

VMware

$148.15

0.11 (0.07%)

PVTL

Pivotal Software

$13.69

0.01 (0.07%)

CBLK

Carbon Black

$24.52

1.77 (7.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 10

    Sep

  • 10

    Oct

CEQP

Crestwood Equity

$35.83

-0.21 (-0.58%)

06:43
08/23/19
08/23
06:43
08/23/19
06:43
Upgrade
Crestwood Equity rating change  »

Crestwood Equity upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$148.26

0.86 (0.58%)

06:39
08/23/19
08/23
06:39
08/23/19
06:39
Recommendations
Salesforce analyst commentary  »

Salesforce price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 28

    Aug

  • 12

    Dec

  • 16

    Dec

EFOI

Energy Focus

$0.47

-0.0022 (-0.47%)

06:39
08/23/19
08/23
06:39
08/23/19
06:39
Hot Stocks
Energy Focus receives Nasdaq notice of noncompliance »

Energy Focus announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHI

D.R. Horton

$50.34

0.89 (1.80%)

06:37
08/23/19
08/23
06:37
08/23/19
06:37
Initiation
D.R. Horton initiated  »

D.R. Horton initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

HIBB

Hibbett Sports

$17.01

0.845 (5.23%)

06:36
08/23/19
08/23
06:36
08/23/19
06:36
Hot Stocks
Hibbett Sports reports Q2 gross margin 30.3% »

Gross margin was 30.3% of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

HIBB

Hibbett Sports

$17.01

0.845 (5.23%)

06:35
08/23/19
08/23
06:35
08/23/19
06:35
Hot Stocks
Hibbett Sports CEO says 'pleased with the second quarter results' »

Jeff Rosenthal, President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

HIBB

Hibbett Sports

$17.01

0.845 (5.23%)

06:35
08/23/19
08/23
06:35
08/23/19
06:35
Hot Stocks
Hibbett Sports narrows FY20 CapEx view to $18M-$20M from $18M-$22M »

Raises FY20 share…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

PHM

PulteGroup

$33.16

0.27 (0.82%)

06:34
08/23/19
08/23
06:34
08/23/19
06:34
Initiation
PulteGroup initiated  »

PulteGroup initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$46.76

-0.39 (-0.83%)

06:34
08/23/19
08/23
06:34
08/23/19
06:34
Periodicals
Intel introduces new-generation 14nm mobile chips, DigiTimes says »

Monica Chen and Joseph…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 24

    Oct

HPQ

HP Inc.

$18.91

-0.04 (-0.21%)

06:33
08/23/19
08/23
06:33
08/23/19
06:33
Recommendations
HP Inc. analyst commentary  »

HP Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

HIBB

Hibbett Sports

$17.01

0.845 (5.23%)

06:33
08/23/19
08/23
06:33
08/23/19
06:33
Earnings
Hibbett Sports raises FY20 adj. EPS view to $2.15-$2.25 from $2.00-$2.15 »

FY20 consensus $2.10.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

KBH

KB Home

$28.48

0.31 (1.10%)

06:32
08/23/19
08/23
06:32
08/23/19
06:32
Initiation
KB Home initiated  »

KB Home initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.